BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS),

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT5528 will be presented during an e-poster session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program on May 29-31, 2020

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a retrospective analysis of Phase 2b trial data demonstrating the potential renal protective activity of lead candidate avasopasem manganese (GC4419),

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational therapy trilaciclib in small cell lung cancer (SCLC) will be presented on May 29 at the ASCO20 Virtual Scientific Program of the American Society of Clinical Oncology (ASCO)

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present updated durability, safety and immunogenicity clinical data from Part A of its ongoing Phase 1/2a trial for GEN-009, the company’s lead neoantigen vaccine candidate at the virtual 2020 American Society for Clinical Oncology (ASCO) Annual Meeting from May 29-31.

VBL Therapeutics (Nasdaq: VBLT), today announced that it has closed the previously announced offering of 5,142,857 ordinary shares of the Company, at a purchase price of $1.575 per share, in a registered direct offering priced at-the-market under Nasdaq rules

Eisai announced today the presentation of data and analyses across six cancer types at the American Society of Clinical Oncology’s ASCO20 Virtual Scientific Program from May 29-31.

Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, announced the pricing of its underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $4.75 per share, before deducting underwriting discounts and commissions.

Kiniksa Pharmaceuticals, Ltd. announced the pricing of its public offering of 2,400,000 of its Class A common shares at a public offering price of $18.25 per share, before underwriting discounts and commissions.

BerGenBio ASA, will announce its results for the first quarter 2020 on Tuesday 19 May 2020.